Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma. Yang Z, Li F, Huang Y, Yin N, et al. J Nucl Med 2022 Feb 24. pii: jnumed.121.263151. doi: 10.2967/jnumed.121.263151.

Read + Share

Amedeo Smart

Independent Medical Education

Yang Z, Li F, Huang Y, Yin N, et al. Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma. J Nucl Med 2022 Feb 24. pii: jnumed.121.263151. doi: 10.2967/jnumed.121.263151.
PMID: 35210298